Senores Pharmaceuticals Limited has informed the Exchange regarding Monitoring Agency Report for the quarter ended March 31, 2025
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals has filed the Monitoring Agency Report from CARE Ratings covering use of its Rs. 500 crore IPO proceeds (fresh issue, Dec 20-24, 2024) for Q4FY25. During the quarter, the company utilized Rs. 146.75 crore, taking cumulative utilization to Rs. 156.75 crore, leaving Rs. 343.25 crore unutilized. The unutilized amount of Rs. 343.95 crore has been parked in fixed deposits with HDFC and ICICI Banks (earning 5.5%-7.4%) and in monitoring/public offer bank accounts. The Monitoring Agency flagged delays in two objects — Havix subsidiary loan repayment (Rs. 3.91 cr of Rs. 20.22 cr deployed) and working capital funding for SPI/Ratnatris (Rs. 22.41 cr of Rs. 23.96 cr scheduled deployed) — but both have since been completed. No deviation from stated objects or major deviation from earlier reports was observed. The largest unutilized heads remain the Atlanta sterile injections capex (Rs. 107 cr, planned for FY26) and the inorganic growth/GCP bucket (Rs. 118.65 cr unutilized).
This is a routine SEBI-mandated compliance filing. No deviation from stated IPO objects and no material concerns flagged by the Monitoring Agency. The delay-related items have been resolved, and idle funds are earning market interest, which is neutral to mildly positive for shareholders.